Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 11/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 5/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 11/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10100782 | 0.94 | EPHX2 (0.43) | EPHX2ACVR1RIPK2NOD2CHEK2 | |
| SCHEMBL10100601 | 0.84 | TGFBR1 (0.36) | ACVR1RIPK2NOD2TGFBR1 | |
| SCHEMBL2357723 | 0.84 | LRRK2 (0.44) | ACVR1RIPK2NOD2TGFBR1 | |
| SCHEMBL982912 | 0.81 | EPHX2 (0.47) | EPHX2CHEK2CHEK1CYP2A6 | |
| SCHEMBL10100637 | 0.80 | ALOX5AP (0.40) | EPHX2CHEK2CHEK1 | |
| SCHEMBL10100784 | 0.79 | TGFBR1 (0.35) | ACVR1RIPK2NOD2TGFBR1 | |
| SCHEMBL10100781 | 0.79 | LRRK2 (0.43) | ACVR1RIPK2NOD2TGFBR1 | |
| SCHEMBL10100792 | 0.79 | EPHX2 (0.40) | EPHX2CHEK2CHEK1CYP2A6 | |
| SCHEMBL10100590 | 0.78 | EPHX2 (0.43) | EPHX2CHEK2CHEK1CYP2A6 | |
| SCHEMBL10100635 | 0.77 | EPHX2 (0.38) | EPHX2CHEK2CHEK1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2010048131-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | EPHX2 2778/4885ACVR1 576/4885RIPK2 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.